» Articles » PMID: 12297832

Tissue Inhibitor of Metalloproteinases-1 Attenuates Spontaneous Liver Fibrosis Resolution in the Transgenic Mouse

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2002 Sep 26
PMID 12297832
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

It has been suggested that the tissue inhibitor of metalloproteinases-1 (TIMP-1) is involved in spontaneous resolution of liver fibrosis. The aim of this study was to investigate whether TIMP-1 altered spontaneous resolution of liver fibrosis in conjunction with matrix metalloproteinases (MMP) inhibition and hepatic stellate cell (HSC) activation. The livers of liver-targeted TIMP-1 transgenic (TIMP-Tg) and control hybrid (Cont) mice were harvested at 0, 3, 7, and 28 days following spontaneous recovery from CCl(4)-induced liver fibrosis. The extent of fibrosis resolution, MMP expression, alpha-smooth-muscle actin (alpha-SMA) positive cells, and procollagen-(I) messenger RNA (mRNA) in the liver were assessed at the respective periods in both groups. We also examined the effect of TIMP-1 on HSC apoptosis. The TIMP-Tg mice showed significantly attenuated resolution of spontaneous liver fibrosis compared with the Cont mice. The hydroxyproline content, number of alpha-SMA positive cells, and procollagen-(I) mRNA rapidly decreased with time in the Cont mice, whereas these markers were little changed in TIMP-Tg mice. The level of the active form of metalloproteinases-2 (MMP-2) in the TIMP-Tg mice was less than that in the Cont mice. TIMP-1 markedly decreased the nonparenchyma apoptotic cells in the liver fibrosis resolution model, and it also inhibited HSC apoptosis associated with suppression of caspase-3 activity in vitro. In conclusion, TIMP-1 significantly attenuated spontaneous resolution of liver fibrosis by the combination of a net reduction of the MMP activity and suppression of apoptosis in HSC.

Citing Articles

TIMP-1 Promotes Expression of MCP-1 and Macrophage Migration by Inducing Fli-1 in Experimental Liver Fibrosis.

Huang X, Wang X, Wang Y, Shen S, Chen W, Liu T J Clin Transl Hepatol. 2024; 12(7):634-645.

PMID: 38993513 PMC: 11233975. DOI: 10.14218/JCTH.2023.00514.


Binding of berberine to PEBP1 synergizes with sorafenib to induce the ferroptosis of hepatic stellate cells.

Xie Z, Zhou Y, Lin M, Huang C Amino Acids. 2023; 55(12):1867-1878.

PMID: 37814030 DOI: 10.1007/s00726-023-03345-7.


RUN(X) out of blood: emerging RUNX1 functions beyond hematopoiesis and links to Down syndrome.

Rozen E, Ozeroff C, Allen M Hum Genomics. 2023; 17(1):83.

PMID: 37670378 PMC: 10481493. DOI: 10.1186/s40246-023-00531-2.


Understanding the Potential Role of Nanotechnology in Liver Fibrosis: A Paradigm in Therapeutics.

Singh S, Sharma N, Shukla S, Behl T, Gupta S, Anwer M Molecules. 2023; 28(6).

PMID: 36985782 PMC: 10057127. DOI: 10.3390/molecules28062811.


Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System.

Torre P, Motta B, Sciorio R, Masarone M, Persico M Front Med (Lausanne). 2021; 8:781567.

PMID: 34957156 PMC: 8695879. DOI: 10.3389/fmed.2021.781567.